Top Markets
#1 Akedo Akedo +113.13%
#2 TENDIES TENDIES +111.07%
#3 Threshold Network Threshold Network +50.77%
#4 Verus Coin Verus Coin +44.05%
#5 Mubarak Mubarak +27.18%
#6 Bitway Bitway +22.68%
#7 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
#8 OSK OSK +16.18%
#9 MultiversX MultiversX +15.96%
#10 Cash Cat Cash Cat +15.94%
Coin of the day
Akedo Akedo
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Classement en actions #17592
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prix de l'action
$8.16
Dernière synchronisation: 2025-06-26
Capitalisation boursière
$234.57M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Regulus Therapeutics Inc. (RGLS)

Catégorie

Healthcare
Revenus pour Regulus Therapeutics Inc. (RGLS)
Revenus en Mar 2025 TTM : $340.00K
Selon les derniers rapports financiers de Regulus Therapeutics Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $340.00K. En 2023, l'entreprise a réalisé un chiffre d'affaires de 0.00 égal à le chiffre d'affaires de l'année 2022, qui était de 0.00. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Regulus Therapeutics Inc. de 2010 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $340.00K 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 $10.01M 46.46%
2019 $6.83M 9,388.89%
2018 $72.00K 0.00%
2017 $72.00K -93.97%
2016 $1.19M -94.25%
2015 $20.76M 170.69%
2014 $7.67M -60.81%
2013 $19.57M 54.09%
2012 $12.70M -7.90%
2011 $13.79M 60.32%
2010 $8.60M 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 3,712,929.41%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 1,770,866.86%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 655,194.12%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 4,630,584.45%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH